DEXTENZA VS. PREDNISOLONE ACETATE 1% Macular Edema With Diabetic Retinopathy After Cataract Surgery

Overview

The complicated schedules for administering topical steroid eye drops combined with forgetfulness and physical difficulties instilling the drops may compromise compliance; which in turn could increase the risk for secondary complications such as PME post-cataract surgery, especially in a high-risk diabetic population. Dextenza, a sustained- release steroid insert, could help preclude adherence difficulties and provide better bioavailability, being as effective as, or more effective than steroid drops in preventing PME. The aim of this study is to assess the incidence of PME in diabetic patients undergoing cataract surgery when comparing the Dextenza insert to topical prednisolone acetate 1% drops.

Full Title of Study: “DEXTENZA VS. PREDNISOLONE ACETATE 1% in the Incidence of Pseudophakic Macular Edema in Patients With Diabetic Retinopathy Undergoing Cataract Surgery”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2022

Detailed Description

This prospective, open-label, single-center, randomized, fellow-eye, investigator-sponsored clinical study seeks to investigate the incidence of PME in diabetic patients with any level of background diabetic retinopathy undergoing cataract surgery treated with a 0.4mg dexamethasone intracanalicular insert when compared to standard of care prednisolone acetate 1% QID/1 week, TID/ 1 week, BID/ 1 week, QD/1 week. Topical NSAIDs will not be used in this study and all patients will receive an intracameral injection of moxifloxacin at the end of the surgical procedure. After screening a patient for inclusion and exclusion criteria, and gaining informed consent, each eye will undergo cataract surgery on separate days. The second eye will be operated on within 60 days of the first eye's surgery. One eye will be randomized to receive the dexamethasone insert using a coin flip. The other eye will be prescribed a prednisolone acetate 0.1% eye drop QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week regimen. The dexamethasone insert will be placed 2-4 days before surgery (Day -4 to Day-2) and those randomized to receive prednisolone acetate will start 2-4 days before surgery. After surgery, each eye will be followed for a period of approximately 60 days, consisting of four post-op follow-up visits (eight total post-op visits per patient). Primary and secondary endpoints will be assessed alongside standard-of-care procedures at all study visits . Adjusting for the enrollment period, the study will last a total of approximately 12 months.

Interventions

  • Drug: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
    • Prednisolone Acetate 1% ophthalmic drops

Arms, Groups and Cohorts

  • Experimental: Dextenza
    • Sustained release Dexamethasone 0.4mg
  • Active Comparator: Prednisolone Acetate 1%
    • Prednisolone Acetate Ophthalmic drops

Clinical Trial Outcome Measures

Primary Measures

  • To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure.
    • Time Frame: 7 days
    • Percentage of eyes that developed post-surgical PME in each group measured on fluorescein angiography at Day 7 on Optical Coherence Tomography at Day 7 by a masked grader.
  • To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure.
    • Time Frame: 30 days
    • Percentage of eyes that developed post-surgical PME in each group measured on optical coherence tomography at Day 30 by a masked grader.
  • To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure.
    • Time Frame: 60 days
    • Percentage of eyes that developed post-surgical PME in each group measured on fluorescein angiography at Day 60 and on optical coherence tomography at Day 60 by a masked grader.

Secondary Measures

  • Incidence of central subfield thickness (CST) at Day 7 post op as seen on optical coherence tomography (OCT)
    • Time Frame: 7days
    • Mean central subfield thickness (CST) at Day 7 post op in each group and comparison between groups.
  • Incidence of central subfield thickness (CST) at Day 7 post op as seen on optical coherence tomography (OCT)
    • Time Frame: 30 days
    • Mean central subfield thickness (CST) at Day 30 post op in each group and comparison between groups.
  • Incidence of central subfield thickness (CST) at Day 60 post op as seen on optical coherence tomography (OCT)
    • Time Frame: 60 days
    • Mean central subfield thickness (CST) at Day 60 post op in each group and comparison between groups.
  • To measure the change in CST inflammation outcomes and in diabetic patients as seen on optical coherence tomography (OCT), Dextenza compared to topical prednisolone acetate 1%.
    • Time Frame: 7 days
    • Mean change in CST from Baseline at Day 7, Day 30 and Day 60 and comparison between groups.
  • To measure the change in CST inflammation outcomes and in diabetic patients as seen on optical coherence tomography (OCT), Dextenza compared to topical prednisolone acetate 1%.
    • Time Frame: 30 days
    • Mean change in CST from Baseline at Day 7, Day 30 and Day 60 and comparison between groups.
  • To measure the change in CST inflammation outcomes and in diabetic patients as seen on optical coherence tomography (OCT), Dextenza compared to topical prednisolone acetate 1%.
    • Time Frame: 60 days
    • Mean change in CST from Baseline at Day 7, Day 30 and Day 60 and comparison between groups.
  • To measure the effect of 0.4mg dexamethasone intracanalicular insert in vision in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1%.
    • Time Frame: 7 days
    • Difference of mean ETDRS Best Corrected Visual Acuity (BCVA) between groups at Day 7 post op
  • To measure the effect of 0.4mg dexamethasone intracanalicular insert in vision in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1%.
    • Time Frame: 30 days
    • Difference of mean ETDRS Best Corrected Visual Acuity (BCVA) between groups at Day 30 post op
  • To measure the effect of 0.4mg dexamethasone intracanalicular insert in vision in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1%.
    • Time Frame: 60 days
    • Difference of mean ETDRS Best Corrected Visual Acuity (BCVA) between groups at Day 60 post op
  • Difference patients with absence of anterior chamber (AC) cells at Day 7 post op
    • Time Frame: 7 days
    • Percentage of patients who had absence of Anterior Chamber (AC) cells at Day 7
  • Difference patients with absence of anterior chamber (AC) cells at Day 30 post op
    • Time Frame: 30 days
    • Percentage of patients who had absence of Anterior Chamber (AC) cells at Day 30
  • Difference patients with absence of anterior chamber (AC) cells at Day 60 post op
    • Time Frame: 30 days
    • Percentage of patients who had absence of Anterior Chamber (AC) cells at Day 60
  • Self reported patient experience of comfort
    • Time Frame: 60 days
    • Self-reported patient experience of comfort (right eye vs. left eye) at Day 60.
  • Rescue Therapy
    • Time Frame: 60 days
    • Percentage of eyes rescued in each group.

Participating in This Clinical Trial

Inclusion Criteria

  • Binocular – >18 years old – Any level of Background Diabetic Retinopathy – Cataract surgery candidate in each eye – Pre-operative OCT and Fluorescein Angiography showing no Macular edema Exclusion Criteria:

  • Participant cannot complete second eye operation within 60 days of the first cataract surgery – Maintains regular use of systemic or ocular steroids at time of enrollment – Maintains regular use of systemic or ocular non-steroidal anti-inflammatory drugs at time of enrollment – Anterior chamber cells present at time of enrollment – Recent febrile illness that precludes or delays participation for 90 days – Pregnancy or lactation – Known allergy to dexamethasone – Known allergy to prednisolone – Preexisting retinal disease including uveitis, nondiabetic retinal disease, choroidal disorders, diabetic macular edema. – Posterior capsule rupture or other intraoperative complication in first eye operated on – Amblyopia – Anti-VEGF injections within 6 months prior to surgery day. – Intraocular steroid injection within 6 months prior to surgery day. – Intraocular surgeries within 6 months prior to surgery day. – Laser photocoagulation within 30 days prior to surgery day. – Any type of eye inflammation – Any punctum inflammation or dacryocystitis

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Ophthalmic Consultants of the Capital Region
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Robert Feldman, MD, Principal Investigator, Ophthalmic Consultants of the Capital Region
  • Overall Contact(s)
    • Suzanne Alterman, RN, BSN, 518-274-3123, salterman@ophthalmicconsultants.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.